Abstract BACKGROUND Paediatric-type diffuse high-grade glioma (PDHGG) are brain tumours occurring largely in children, classified into distinct subgroups based upon their location and defining molecular alterations, with very poor clinical outcomes. The presence of a wide diversity of genotypically- and phenotypically-distinct subclones within individual tumours provides a substantial barrier to developing effective treatments. METHODS To understand their role, and how this may be exploited therapeutically, we established 218 subclones in vitro from 8 patient-derived PDHGG different cell lines, and characterised them using single-cell and bulk multi-omic approaches linked to high-content phenotypic screening. RESULTS Highly migratory subpopulations of diffuse midline glioma (DMG) cells were isolated, whereby RNAseq and proteomics identified a specific metaprogram associated with migration, enriched in AP-1 target genes, and common across a series of DMG patient-derived cells. Data integration of scRNAseq/scATACseq showed an opening of the chromatin at loci such as the early development transcription factors FOS and JUN (AP-1 targets) associated with their overexpression in highly migratory cells. Co-culturing these subclones with less motile patient-matched counterparts conferred an enhanced migratory capacity in these cells, so we sought to abrogate this via high-throughput screening of over 900 compounds aimed at selectively targeting DMG subclones grown in co-culture. Inter-clonal interactions were disrupted by a diverse set of compound classes including previously identified secreted protein inhibitors (MMP2/9i). Moreover, hits were seen with numerous neuroactive drugs inhibiting a series of neural receptors, ion channels, and transporters shown to be highly expressed in subpopulations of DMG cells, and linked to a common mechanism of action via AP-1. CONCLUSIONS Clinically available neuroactive drugs may therefore represent a novel therapeutic approach in targeting highly migratory cells within DMG, which undergo chromatin remodelling to confer a pro-tumorigenic programme via upregulation of AP-1 targets.